Alignment of counseling around topical steroids will improve morbidity associated with lichen sclerosus

Abstract

Ultrapotent topical steroids are the first-line treatment for lichen sclerosus, a chronic inflammatory disease that most commonly affects the genital and anal regions. Lichen sclerosus can cause profound morbidity and can progress to squamous cell carcinoma. Therefore, treatment is essential to mitigate these complications. Despite the accessibility, relative affordability, and safety profiles of topical steroids, many clinicians, pharmacists, and patients are hesitant to use them. This paper outlines the importance of chronic steroid use for managing lichen sclerosus to prevent disease sequelae and aims to educate readers on ways physicians and pharmacists can mitigate steroid phobia.